Quest Diagnostics Incorporated cash flow to debt ratio of 27.26% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Quest Diagnostics Incorporated's free cash flow has increased 49.50% from $909.00M last year to $1.36B, signaling increasing performance

Quest Diagnostics Incorporated's debt to equity ratio is 0.85, which means that the company's assets are unhealthy financed, signaling financial risk.

Quest Diagnostics Incorporated's debt has decreased relative to shareholder equity from 1.05 last year to 0.85 today, signaling strengthened financials

Quest Diagnostics Incorporated has a net debt to EBITDA ratio of 2.96x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Quest Diagnostics Incorporated's interest coverage ratio of 6.24 indicates that earnings with good margin can cover interest payments on company debt

Quest Diagnostics Incorporated's profit margin has increased (4.13%) in the last year from 8.82% to 9.19%, signaling increasing performance

Quest Diagnostics Incorporated's short-term assets of $2.38B exceed its short-term liabilities of $2.28B

Quest Diagnostics Incorporated's return on assets of 6.27% is higher than the 5.00% threshold, indicating efficient asset utilization

Quest Diagnostics Incorporated's return on equity of 14.49%, is lower than 15.00%, indicating bad performance

Quest Diagnostics Incorporated's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Quest Diagnostics Incorporated had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Quest Diagnostics Incorporated has positive free cash flow, indicating the company generates cash after capital expenditures

Quest Diagnostics Incorporated has a free cash flow yield of 5.18%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Quest Diagnostics Incorporated's yearly earnings has increased 13.89% since last year from $871.00M to $992.00M, signaling increasing performance

Quest Diagnostics Incorporated's yearly revenue has increased 11.78% since last year from $9.87B to $11.04B, signaling increasing performance

ROIC 8.25% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Quest Diagnostics Incorporated's 3-year revenue CAGR of 3.74% is positive, indicating growing revenue over the past 3 years

Quest Diagnostics Incorporated had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Quest Diagnostics Incorporated had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Quest Diagnostics Incorporated is overvalued relative to its fair value price of 67.23 based on Discounted Cash Flow model

Quest Diagnostics Incorporated has an earnings yield of 4.06%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Quest Diagnostics Incorporated is overvalued relative to its fair value price of 80.04 based on EBITDA multiple model

Quest Diagnostics Incorporated has an EV/EBITDA ratio of 14.92x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Quest Diagnostics Incorporated is overvalued relative to its fair value price of 168.43 based on Earnings Fair Value model

Quest Diagnostics Incorporated's earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Quest Diagnostics Incorporated has a price-to-book ratio of 3.34x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Quest Diagnostics Incorporated has a price-to-sales ratio of 2.26x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue